for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Obseva SA

OBSV.OQ

Latest Trade

8.83USD

Change

0.00(0.00%)

Volume

13,165

Today's Range

8.78

 - 

9.38

52 Week Range

8.22

 - 

19.40

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
8.83
Open
9.15
Volume
13,165
3M AVG Volume
0.93
Today's High
9.38
Today's Low
8.78
52 Week High
19.40
52 Week Low
8.22
Shares Out (MIL)
43.89
Market Cap (MIL)
386.04
Forward P/E
-2.93
Dividend (Yield %)
--

Next Event

Obseva SA at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Obseva SA Files For Mixed Shelf Of Upto $250 Million

Obseva To Increase Issued Share Capital

Obseva Appoints Dr. Elizabeth Garner As Chief Medical Officer

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Obseva SA

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis (phase 2b of clinical trials) and uterine fibroids (phase 3 of clinical trials); Nolasiban (OBE001), an oral oxytocin receptor antagonist undergoing phase 3 of clinical trials, with the potential to inhibit uterine contractions at the time of embryo transfer, thereby enhancing embryo implantation during assisted reproductive technologies (ART), and OBE022, an oral and selective prostaglandin F2 alpha (PGF2a) receptor antagonist designed to control preterm labor (phase 2a of clinical trials).

Industry

Biotechnology & Drugs

Contact Info

Chemin des Aulx 12

+41.22.5521558

http://www.obseva.com

Executive Leadership

Frank Verwiel

Independent Chairman of the Board

Ernest Loumaye

Chief Executive Officer, Director

Timothy M. Adams

Chief Financial Officer

Jean-Pierre Gotteland

Chief Scientific Officer, Head of Research & Development

Elizabeth Garner

Chief Medical Officer

Key Stats

1.63 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1.400

2017

-2.250

2018

-1.910

2019(E)

-3.011
Price To Earnings (TTM)
--
Price To Sales (TTM)
29,695.75
Price To Book (MRQ)
4.11
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-70.84
Return on Equity (TTM)
-61.94

Latest News

Swiss stocks - Factors to watch on September 12

The Swiss blue-chip SMI was seen opening 0.6 percent higher at 10,156 points -- what would be a record -- on Thursday, according to premarket indications by bank Julius Baer.

BRIEF-ObsEva Announces New Composition Of Its Executive Committee

* OBSEVA ANNOUNCES NEW COMPOSITION OF ITS EXECUTIVE COMMITTEE

BRIEF-Obseva SA Files For Mixed Shelf Of Upto $250 Million

* OBSEVA SA FILES FOR MIXED SHELF OF UPTO $250 MILLION - SEC FILING Source text: (https://bit.ly/2yHP55N) Further company coverage:

Swiss stocks - Factors to watch on Aug 7

The Swiss blue-chip SMI was seen opening 0.1 percent lower at 9,548 points on Wednesday, according to premarket indications by bank Julius Baer.

Swiss stocks - Factors to watch on July 18

Here are some of the main factors that may affect Swiss stocks on Thursday:

BRIEF-Obseva To Increase Issued Share Capital

* OBSEVA TO INCREASE ISSUED SHARE CAPITAL BY CREATING ADDITIONAL TREASURY SHARES

Swiss stocks - Factors to watch on July 1

The Swiss blue-chip SMI was seen opening 0.7 percent higher at 9,969 points on Monday, according to premarket indications by bank Julius Baer .

BRIEF-Obseva Appoints Dr. Elizabeth Garner As Chief Medical Officer

* OBSEVA APPOINTS INDUSTRY EXPERT AS CHIEF MEDICAL OFFICER TO FURTHER ADVANCE ITS PHASE 3 CLINICAL PROGRAMS

Swiss stocks - Factors to watch on June 19

The Swiss blue-chip SMI was seen opening 0.1 percent lower at 9,977 points on xxday, according to premarket indications by bank Julius Baer .

BRIEF-Obseva Progressing Toward U.S. Phase 3 Trial For Nolasiban In IVF Following Recent FDA Meeting

* OBSEVA PROGRESSING TOWARD U.S. PHASE 3 TRIAL FOR NOLASIBAN IN IVF FOLLOWING RECENT FDA MEETING

Swiss stocks - Factors to watch on June 4

The Swiss blue-chip SMI was seen opening 0.2 percent lower at 9,585 points on Tuesday, according to premarket indications by bank Julius Baer .

Swiss stocks - Factors to watch on May 9

The Swiss blue-chip SMI was seen opening 0.3 percent lower at 9,595 points on Thursday, according to premarket indications by bank Julius Baer .

Swiss stocks - Factors to watch on Nov. 28

The Swiss blue-chip SMI was seen opening 0.3 percent higher at 8,925 points on Wednesday, according to premarket indications by bank Julius Baer.

Swiss stocks - Factors to watch on Oct. 10

The Swiss blue-chip SMI was seen opening 0.2 percent lower at 8,950 points on Wednesday, according to premarket indications by bank Julius Baer.

BRIEF-Obseva SA Presents Clinical Data From Phase III Implant 2 Trial Of Nolasiban In IVF At ASRM

* PRESENTS CLINICAL DATA FROM PHASE III IMPLANT 2 TRIAL OF NOLASIBAN IN IVF AT AMERICAN SOCIETY OF REPRODUCTIVE MEDICINE (ASRM) ANNUAL MEETING

Swiss stocks - Factors to watch on Oct. 3

The Swiss blue-chip SMI was seen opening little changed at 9,090 points on Wednesday, according to premarket indications by bank Julius Baer .

Swiss stocks - Factors to watch on Aug 8

The Swiss blue-chip SMI was seen opening little changed at 9,198 points on Wednesday, according to premarket indications by bank Julius Baer .

Swiss stocks - Factors to watch on July 13

The Swiss blue-chip SMI was seen opening up 0.3 percent at 8,844 points on Friday, according to premarket indications by bank Julius Baer .

ObsEva plans Swiss listing; trading debut on July 13

ObsEva <OBSV.O>, a Switzerland-based drug development company, said on Friday it plans a secondary listing on the SIX Swiss Exchange in Zurich and trading debut on July 13, as the firm seeks to gain more visibility among European investors.

Swiss stocks - Factors to watch on July 6

The Swiss blue-chip SMI was seen opening 0.5 percent higher at 8,714 points on Friday, according to premarket indications by bank Julius Baer .

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up